But_home
But_blogshome
But_forum
Icon_rss_infobarSubscribe to receive updates
on new articles and posts from this blog.
 
Latest 5 articles from heartwire

LIFENOX: No advantage of VTE prophylaxis in hospitalized medical service patients

Btn-download-en
Posted Jan 13, 2012 at 09:20 AM, EDT by Samuel Goldhaber

The surprising results of the LIFENOX trial—which failed to show an advantage of daily enoxaparin vs placebo to reduce mortality in the acute-care setting—challenge dogma. What explains these results?

See also:

Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2012; 365:2463-2472. Abstract.

Enoxaparin prophylaxis doesn't cut mortality in acute-care setting

1 Comments | Add your own comments | Permalink

Comments

How many additional research studies will be conducted to further investigate VTE prophylaxis benefits for specific populations?  Additionally, how will this affect the AHA's evidence-based measure?

 Thank you...


Posted by Maggie, Jan 23, 2012 at 09:54 AM, EDT
Reply to this comment

Add your own comments



 


This blog on theheart.org is a sounding board for healthcare providers, clinicians, and researchers, and is not intended to supply answers or advice to patients. We reserve the right to remove posts containing inappropriate language, promotional content, personal agendas or hostile intent, and posts from patients asking for medical advice.

In the interest of promoting a balanced exchange, please disclose any relevant relationships or conflicts of interest when posting your comment.

The views and opinions expressed herein are those of the blogger and do not necessarily reflect those of theheart.org.